Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival. METHODS: We randomly assigned patients to receive either ribociclib or placebo in addition to endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen). Overall survival was evaluated with the use of a stratified log-rank test and summarized with the use of Kaplan-Meier methods. RESULTS: A total of 672 patients were included in the intention-to-treat population. There were 83 deaths among 335 patients (24.8%) in the ribociclib group and 109 deaths among 337 patients (32.3%) in the placebo group. The addition of ribociclib to endocrine therapy resulted in significantly longer overall survival than endocrine therapy alone. The estimated overall survival at 42 months was 70.2% (95% confidence interval [CI], 63.5 to 76.0) in the ribociclib group and 46.0% (95% CI, 32.0 to 58.9) in the placebo group (hazard ratio for death, 0.71; 95% CI, 0.54 to 0.95; P = 0.00973 by log-rank test). The survival benefit seen in the subgroup of 495 patients who received an aromatase inhibitor was consistent with that in the overall intention-to-treat population (hazard ratio for death, 0.70; 95% CI, 0.50 to 0.98). The percentage of patients who received subsequent antineoplastic therapy was balanced between the groups (68.9% in the ribociclib group and 73.2% in the placebo group). The time from randomization to disease progression during receipt of second-line therapy or to death was also longer in the ribociclib group than in the placebo group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.55 to 0.87). CONCLUSIONS: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer. No new concerns regarding toxic effects emerged with longer follow-up. (Funded by Novartis; MONALEESA-7 ClinicalTrials.gov number, NCT02278120.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in view of the OS benefit seen in several trials,36, 37, 38, 39, 40, 41, 42 both in the first- and second-line settings”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“the combination of tamoxifen and ribociclib led to increased cardiotoxicity (arrhythmia)”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [36]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationFinn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationSledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Self-citationOverall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSlamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9909 · Cited by 1,121
Self-citation
Cited by
Items 201–300 of 1,000
Yousuf, M., Alam, M., Shamsi, A., Κhan, P., Hasan, G. M., Haque, Q. M. R., & Hassan, M. I. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.07.156 · Cited by 37
de Kouchkovsky, I., Rao, A., Carneiro, B. A., Zhang, L., Lewis, C., Phone, A., Small, E. J., Friedlander, T. W., Fong, L. H., Paris, P. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4302 · Cited by 39
Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets
Milioli, H. H., Alexandrou, S., Lim, E., & Caldon, C. E. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0501 · Cited by 40
Shah, A. N., Metzger, O., Bartlett, C. H., Liu, Y., Huang, X., & Cristofanilli, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0729 · Cited by 39
Biologic therapy for advanced breast cancer: recent advances and future directions
Tarantino, P., Morganti, S., & Curigliano, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1752176 · Cited by 42
“Additionally, ribociclib was tested in combination with AI or tamoxifen (plus goserelin) in premenopausal women in the phase 3 MONALEESA-7 trial, showing a relevant and statistically significant OS improvement in the study cohort [20].”
MethodYano, S., Tazawa, H., Kagawa, S., Fujiwara, T., & Hoffman, R. M. (2020) · Cancers · doi:10.3390/cancers12092655 · Cited by 40
Neven, P., Rugo, H. S., Tolaney, S. M., Iwata, H., Toi, M., Goetz, M. P., Kaufman, P. A., Lu, Y., Haddad, N., Hurt, K. C., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01463-2 · Cited by 39
Self-citationMo, H., Renna, C., Moore, H. C. F., Abraham, J., Kruse, M. L., Montero, A. J., LeGrand, S. B., Wang, L., & Budd, G. T. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.10.002 · Cited by 38
Masri, J. E., & Phadke, S. D. (2022) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000721 · Cited by 45
Sharifi, M. N., Anandan, A., Grogan, P. T., & O'Regan, R. M. (2020) · Cancer · doi:10.1002/cncr.32931 · Cited by 36
“71, crossing the prespecified superiority boundary.(25) In prespecified subgroup analyses, there was no significant PFS benefit in patients who experienced disease progression within 12 months after completing adjuvant ET (30% of the population), consistent with what was seen in PALOMA-3, although not”
ResultUpdates in endocrine therapy for metastatic breast cancer
Manohar, P. M., & Davidson, N. E. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0255 · Cited by 40
Thill, M., Friedrich, M., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2021) · Breast Care · doi:10.1159/000516420 · Cited by 34
Self-citationLncRNA AGPG Confers Endocrine Resistance in Breast Cancer by Promoting E2F1 Activity
Yu, S., Wang, Y., Gong, X. Q., Fan, Z., Wang, Z., Liang, Z., Wu, R., Cao, B., Wang, N., Bi, C., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0015 · Cited by 35
Petroni, G., Galassi, C., Gouin, K. H., Chen, H., Buqué, A., Bloy, N., Yamazaki, T., Sato, A., Beltrán‐Visiedo, M., Campia, G., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01007-z · Cited by 39
Schettini, F., Giuliano, M., Giudici, F., Conte, B., Placido, P. D., Venturini, S., Rognoni, C., Leo, A. D., Locci, M., Jérusalem, G., et al. (2021) · Cancers · doi:10.3390/cancers13061458 · Cited by 39
Bertho, M., Fraisse, J., Patsouris, A., Cottu, P. H., Arnedos, M., Pérol, D., Jaffré, A., Gonçalvès, A., Lebitasy, M.-P., D’Hondt, V., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920987657 · Cited by 34
de Oliveira, K. A., Sengupta, S., Yadav, A. K., & Clarke, R. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1083048 · Cited by 39
Brandão, M., Maurer, C., Ziegelmann, P. K., Ponde, N. F., Ferreira, A. R., Martel, S., Piccart, M. J., de Azambuja, E., Debiasi, M., & Lambertini, M. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000842 · Cited by 34
Kato, S., Okamura, R., Adashek, J. J., Khalid, N. K., Lee, S., Nguyen, V. T., Sicklick, J. K., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.142547 · Cited by 36
Martín, M., Zielinski, C. C., Ruíz‐Borrego, M., Carrasco, E., Ciruelos, E., Muñoz-Mateu, M., Bermejo, B., Vila, M. M., Csőszi, T., Antón, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.006 · Cited by 35
Lee, J. S., Hackbart, H., Cui, X., & Yuan, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411791 · Cited by 37
“Sci. 2023, 24, 11791 2 of 13 MONARCH-3 [8] Abemaciclib plus NSAI* 493 (2:1) 28.1 0.54 pending Placebo plus NSAI* 14.7 1 Endocrine resistant MBC, any menopausal status PALOMA-3 [9,10] Palbociclib plus Fulvestrant 521 (2:1) 9.5 0.46 34.9 0.81 Placebo plus Fulvestrant 4.6 1 28.0 1 MONARCH-2 [11,12] Abemaciclib plus Fulve…”
InfluentialFerro, A., Campora, M., Caldara, A., Lisi, D. D., Lorenzi, M., Monteverdi, S., Mihai, R., Bisio, A., Dipasquale, M., Caffo, O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123611 · Cited by 32
Maculaitis, M. C., Liu, X., Will, O., Hanson, M., McRoy, L., Berk, A. R., & Crastnopol, M. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s254934 · Cited by 32
Zhu, L., Wang, M., Luo, X., Li, H., Han, S., Du, Q., & Zhai, Q. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-5110 · Cited by 32
“While in two trials that reported OS data, MONALEESA-3 trial discovered that ribociclib plus fulvestrant and fulvestrant alone existed no significant differences (48) and as the only trial focusing on pre-/ perimenopausal population, MONALEESA-7 reported that ribociclib plus endocrine therapy showed notably longer OS…”
ResultBardia, A., Cortés, J., Hurvitz, S. A., Delaloge, S., Iwata, H., Shao, Z., Kanagavel, D., Cohen, P., Liu, Q., Cartot‐Cotton, S., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221083956 · Cited by 32
Self-citationEngler, T., Fasching, P. A., Lüftner, D., Hartkopf, A. D., Müller, V., Kolberg, H., Hadji, P., Tesch, H., Häberle, L., Ettl, J., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1880-0087 · Cited by 31
Olivier, T., Haslam, A., & Prasad, V. K. (2023) · BMC Cancer · doi:10.1186/s12885-023-10917-z · Cited by 33
“Post-progression treatment was low in both arms (73% in the control arm, 69% in the experimental arm) [14], when real-life data demonstrated higher access (up to 92% after first-line hormonal therapy) [24].”
BackgroundHR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
Jerzak, K. J., Bouganim, N., Brezden‐Masley, C., Edwards, S. J., Gelmon, K. A., Henning, J., Hilton, J. F., & Sehdev, S. R. (2023) · Current Oncology · doi:10.3390/curroncol30060411 · Cited by 36
“Ribociclib + ET was studied in an exclusively pre/perimenopausal first-line trial (MONALEESA-7), demonstrating significantly longer PFS and OS compared to AI alone (outcomes also summarized in Figure 1) [17,18].”
Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells
Hühn, D., Martí‐Rodrigo, P., Mouron, S. A., Hansel, C. S., Tschapalda, K., Porębski, B., Häggblad, M., Lidemalm, L., Quintela-Fandiño, M., Puigvert, J. C., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13083 · Cited by 39
Cabel, L., Rosenblum, D., Lerebours, F., Brain, E. G. C., Loirat, D., Bergqvist, M., Cottu, P. H., Donnadieu, A. C., Bethune, A., Kiavué, N., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01334-2 · Cited by 32
Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
Clark, A. S., Makhlin, I., & DeMichele, A. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3624 · Cited by 30
“E, estrogen; P2, phosphatidylinositol (4,5)-bisphosphate, also known as PIP2; P3, phosphatidylinositol (3,4,5)-trisphosphate, also”
BackgroundKristensen, K. B., Thomsen, I. M. N., Berg, T., Kodahl, A. R., & Jensen, A. B. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06215-6 · Cited by 31
“Additionally, while data on overall survival in MONALEESA-2 remains immature, overall survival is significantly improved in both MONALEESA 3 & 7 [14, 15].”
BackgroundThree-Dimensional in Vitro Models: A Promising Tool To Scale-Up Breast Cancer Research
Azimian, V., Rafiee, L., Sheikholeslam, M., Shariati, L., Vaseghi, G., Savoji, H., & Javanmard, S. H. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00277 · Cited by 36
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Johnston, S. R. D., Emde, A., Barrios, C. H., Srock, S., Neven, P., Martin, M., Cameron, D., Janni, W., & Gnant, M. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad045 · Cited by 33
Lee, J., Park, H. S., Won, H. S., Yang, J. H., Lee, H. Y., Woo, I. S., Shin, K., Hong, J. H., Yang, Y. J., Chun, S. H., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.451 · Cited by 29
“This finding is in concordance to MONALEESA-7 trial [18], and our data humbly suggest premenopausal patients can be treated equally to postmenopausal patients when adequate ovary function suppression is based.”
BackgroundResultInfluentialLee, S. H., Park, K., Kim, G. M., Jung, K. H., Kang, S. Y., Park, I. H., Kim, J. H., Ahn, H. K., Park, W., Im, S., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.01.014 · Cited by 29
“58 we can compare OS of 41months [3] in premenopausal women to 51 months [19] in postmenopausal patients treated with ET alone (control arm) in the MBC frontline setting.”
BackgroundSelf-citationLiu, Y., Wu, J., Ji, Z., Chen, L., Zou, J., Zheng, J., Lin, W., Cai, J., Chen, Y., Zheng, D., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11322-2 · Cited by 32
“Among the 9 included studies, 6 studies [41–43, 46, 47] involving 3421 patients reported the HR for OS.”
BackgroundEndophytic fungi: A future prospect for breast cancer therapeutics and drug development
Varghese, S., Jisha, M. S., Rajeshkumar, K. C., Gajbhiye, V., Alrefaei, A. F., & Jeewon, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33995 · Cited by 33
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 33
Gagliato, D. D. M., Buzaid, A. C., Pérez-García, J. M., Llombart‐Cussac, A., & Cortés, J. (2020) · Cancers · doi:10.3390/cancers12092480 · Cited by 29
Lu, Y., Yang, S., Ho, Y., & Ji, Y. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1856 · Cited by 28
Self-citationGarcía-Sáenz, J. Á., Martínez-Jáñez, N., Cubedo, R., Jerez, Y., Lahuerta, A., González-Santiago, S., Ferrer, N., Ramos, M., Alonso-Romero, J. L., Antón, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2652 · Cited by 30
Choupani, E., Madjd, Z., Saraygord‐Afshari, N., Kiani, J., & Hosseini, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279522 · Cited by 30
“Hence, CDK4/6 are critical therapeutic targets of BC due to their function in cell-cycle progression and the efficacy of their inhibitors in advanced BC cases [17].”
BackgroundAromatase inhibitors: the journey from the state of the art to clinical open questions
Generali, D., Berardi, R., Caruso, M., Cazzaniga, M. E., Garrone, O., Minchella, I., Paris, I., Pinto, C., & Placido, S. D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1249160 · Cited by 27
Welt, A., Bogner, S., Arendt, M., Kossow, J., Huffziger, A., Pohlkamp, C., Steiniger, H., Becker, U., Alashkar, F., Kohl, M., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03184-z · Cited by 31
Zheng, J., Wu, J., Wang, C., Zhuang, S., Chen, J., & Ye, F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233571 · Cited by 27
Lu, Y., Lee, K. S., Chao, T.-Y., Tseng, L., Chitapanarux, I., Chen, S., Liu, C.-T., Sohn, J., Kim, J. H., Chang, Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1008 · Cited by 27
“A recently concluded phase III study (MONALEESA-7) in premenopausal/perimenopausal women with HRþ, HER2 ABC showed significantly longer OS and PFS in patients treated with ribociclib and endocrine therapy compared with placebo and endocrine therapy (11, 12).”
BackgroundSelf-citationClinical Trials of Oncolytic Viruses in Breast Cancer
Carter, M. E., Koch, A., Lauer, U. M., & Hartkopf, A. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.803050 · Cited by 29
Current Frontline Treatment of Diffuse Large B-Cell Lymphoma
Spinner, M. A., & Advani, R. H. (2022) · ONCOLOGY · doi:10.46883/2022.25920940 · Cited by 31
Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada
Wang, X. Y., Rosen, M. N., Chehade, R., Sahgal, A., Das, S., Warner, E., Saskin, R., Zhang, B., Soliman, H., Chan, K., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.25424 · Cited by 30
Cardoso, F., Rihani, J., Harmer, V., Harbeck, N., Casas, A., Rugo, H. S., Fasching, P. A., Moore, A., de Courcy, J., Pathak, P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad207 · Cited by 29
Self-citationtaweraqi, N. A., & King, R. D. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04787-8 · Cited by 29
“to prolong progression-free survival when combined with hormone therapy [21, 22].”
BackgroundHamilton, E. P., Jeselsohn, R. M., Vahdat, L. T., & Hurvitz, S. A. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01137-5 · Cited by 32
Self-citationJackisch, C., Cortazar, P., Geyer, C. E., Gianni, L., Gligorov, J., Machackova, Z., Perez, E. A., Schneeweiß, A., Tolaney, S. M., Untch, M., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102229 · Cited by 29
Kim, K. N., Shah, P. D., Clark, A. S., Freedman, G. M., Dastgheyb, S., Barsky, A. R., Dreyfuss, A. D., & Taunk, N. K. (2021) · The Breast · doi:10.1016/j.breast.2021.10.001 · Cited by 27
Torres, A. Z., Nussbaum, N. C., Parrinello, C. M., Bourla, A. B., Bowser, B. E., Wagner, S., Tabano, D. C., George, D. J., & Miksad, R. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02091-8 · Cited by 34
Chiu, J. W. Y., Su, F., Joshi, M., Masuda, N., Ishikawa, T., Aruga, T., Zarate, J. P., Babbar, N., Balbin, O. A., & Yap, Y. S. (2023) · BMC Medicine · doi:10.1186/s12916-023-03017-z · Cited by 28
“All 3 MONALEESA trials, MONALEESA-2, MONALEESA-3, and MONALEESA-7, have reported significant progression-free survival (PFS) and overall survival (OS) benefits with ribociclib plus ET in the intention-to-treat populations [2–7].”
BackgroundGüven, D. C., & Şahin, T. K. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07226-1 · Cited by 26
Use of new and emerging cancer drugs: what the cardiologist needs to know
Fabiani, I., Chianca, M., Aimo, A., Emdin, M., Dent, S. F., Fedele, A., Cipolla, C. M., & Cardinale, D. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae161 · Cited by 27
Hui, R., BOER, R. D., Lim, E., Yeo, B. J., & Lynch, J. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13555 · Cited by 33
Liu, C., Huang, Y., Qin, T., You, L., Lu, F., Hu, D., Xiao, R., Xu, Q., Guo, E., Yang, B., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.021 · Cited by 27
Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
Ashai, N., & Swain, S. M. (2023) · Cancers · doi:10.3390/cancers15061855 · Cited by 26
“In the first-line setting, ribociclib combined with endocrine therapy showed an overall survival (OS) benefit [8,9].”
BackgroundMahdi, H., Ray-Coquard, I. L., Lorusso, D., Mirza, M. R., Monk, B. J., & Slomovitz, B. M. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004454 · Cited by 27
Shen, L., Jin, X., Wang, X., Tou, L., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000745 · Cited by 27
Impact of Molecular Profiling on Therapy Management in Breast Cancer
Ultimescu, F., Hudiță, A., Popa, D. E., Olincă, M., Muresean, H. A., Ceaușu, M. C., Stanciu, D. I., Ginghină, O., & Gălățeanu, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13174995 · Cited by 26
“…components are released in circulation from the primary tumor and/or metastatic deposits, by active secretion, or as a result of necrosis or apoptosis, and are currently explored for early BC detection, staging, prognosis, drug resistance, and minimal residual disease (MRD) monitoring.”
BackgroundDecreased ER dependency after acquired resistance to CDK4/6 inhibitors
Iida, M., Toyosawa, D., Nakamura, M., Tsuboi, K., Tokuda, E., Niwa, T., Ishida, T., & Hayashi, S. (2020) · Breast Cancer · doi:10.1007/s12282-020-01090-3 · Cited by 25
Lin, M., Chen, Y., Jin, Y., Hu, X., & Zhang, J. (2020) · Journal of Cancer · doi:10.7150/jca.48944 · Cited by 25
“Moreover, compared to placebo plus nonsteroidal aromatase inhibitor (NSAI)/tamoxifen regimen, the combination of ribociclib and NSAI/tamoxifen showed a significantly prolonged OS (not reached vs 40.9 months, HR=0.71, 95% CI=0.54-0.95, P=0.00973) as first-line or second-line treatment in the MONALEESA-7 trial[20].”
BackgroundInfluentialSeifert, R., Küper, A. T., Tewes, M., Heuschmid, M., Welt, A., Fendler, W. P., Herrmann, K., & Decker, T. W. (2021) · Oncology Research and Treatment · doi:10.1159/000516422 · Cited by 24
Experimental models of endocrine responsive breast cancer: strengths, limitations, and use
Clarke, R. C., Jones, B. C., Sevigny, C. M., Hilakivi-Clarke, L. A., & Sengupta, S. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.33 · Cited by 29
Low, J. L., Lim, E. H., Bharwani, L. D., Wong, A. L. A., Wong, K., Ow, S. G. W., Lim, S. E., Lee, M., Choo, J. R. E., Lim, J. S. J., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221139678 · Cited by 26
Kim, C. G., Kim, M. H., Kim, J. H., Kim, S., Kim, G. M., Kim, T. Y., Ryu, W., Kim, J. Y., Park, H. S., Park, S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-022-01601-4 · Cited by 27
Self-citationEmerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
Li, J., Goh, E. L. K., He, J., Li, Y., Fan, Z., Yu, Z., Yuan, P., & Liu, D. (2023) · Biology · doi:10.3390/biology12050697 · Cited by 32
Cell facilitation promotes growth and survival under drug pressure in breast cancer
Emond, R., Griffiths, J. I., Grolmusz, V. K., Nath, A., Chen, J., Medina, E. F., Sousa, R. S., Synold, T. W., Adler, F. R., & Bild, A. H. (2023) · Nature Communications · doi:10.1038/s41467-023-39242-6 · Cited by 30
Onkar, A., Khan, F., Goenka, A., Rajendran, R. L., Dmello, C., Hong, C. M., Mubin, N., Gangadaran, P., & Ahn, B. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c16839 · Cited by 27
Inoue, K., Masuda, N., Iwata, H., Takahashi, M., Ito, Y., Miyoshi, Y., Nakayama, T., Mukai, H., van der Walt, J., Mori, J., et al. (2021) · Breast Cancer · doi:10.1007/s12282-021-01239-8 · Cited by 25
Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers
Vaz-Luís, I., Francis, P. A., Meglio, A. D., & Stearns, V. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320595 · Cited by 25
Cosimo, S. D., Pérez-García, J. M., Bellet, M., Dalenc, F., Gil‐Gil, M., Borrego, M. R., Gavilá, J., Sampayo-Cordero, M., Aguirre, E., Schmid, P., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac205 · Cited by 28
Re, M. D., Crucitta, S., Omarini, C., Bargagna, I., Mongillo, M., Palleschi, M., Stucci, S., Meattini, I., D'Onofrio, R., Lorenzini, G., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.10.005 · Cited by 23
Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
Klapp, V., Buqué, A., Bloy, N., Sato, A., Yamazaki, T., Zhou, X. K., Formenti, S. C., Galluzzi, L., & Petroni, G. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03964-4 · Cited by 23
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 27
“…women and replicated the results of MONALEESA-2, with a median PFS of 23.8 months in the combination arm compared with 13.0 months in the single arm (HR 0.55, 95% CI 0.44–0.69, p 0 · 0001) [39], and an improvement in OS at 42 months from 46% to 70.2% (HR 0.71, 95% CI 0.54–0.95, p = 0.00973) [41].”
ResultInfluentialGuidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)
Xu, B., & Ma, F. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.12.001 · Cited by 30
Franzoi, M. A., Saúde-Conde, R., Cristóvão‐Ferreira, S., Eiger, D., Awada, A. H., & de Azambuja, E. (2021) · The Breast · doi:10.1016/j.breast.2021.03.002 · Cited by 24
“Moreover, ECOG performance status 0/1 was an eligibility criteria for inclusion into the MONALEESA 2[34] and MONALEESA 7 trials [35].”
MethodElfgen, C., & Bjelic‐Radisic, V. (2021) · Cancers · doi:10.3390/cancers13235994 · Cited by 28
“Likewise, the MONALEESA-7 trial emphasized an OS benefit in selected pre-/perimenopausal women who were not heavily pre-treated (as only 14% received chemotherapy in the advanced setting) [16].”
BackgroundResultIntegrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Loibl, S., & Furlanetto, J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.008 · Cited by 23
“The MONALEESA-2 [23,24], MONALEESA-3 [25,26,33], and MONALEESA-7 [27,28] studies led to the approval of ribociclib in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy or in women who have received prior ET.”
Raghavendra, A. S., Kettner, N. M., Kwiatkowski, D. N., Damodaran, S., Wang, Y., Ramirez, D. L., Gombos, D. S., Hunt, K. K., Shen, Y., Keyomarsi, K., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00722-1 · Cited by 24
Self-citationShah, A. N., Carroll, K., Gerratana, L., Lin, C., Davis, A. A., Zhang, Q., Jacob, S. L., Finkelman, B. S., Zhang, Y., Qiang, W., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06236-1 · Cited by 23
“The benefit of these inhibitors in young women is supported by findings from randomized phase III studies of these agents [7, 24].”
BackgroundMethodExpert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer
Torregrosa, M. D., Barco, S. D., Cotes, A., Roso, L. L., Servitja, S., & Sarrió, R. G. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02766-8 · Cited by 24
Thill, M., Lüftner, D., Kolberg‐Liedtke, C., Albert, U., Banys‐Paluchowski, M., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Fallenberg, E. M., et al. (2022) · Breast Care · doi:10.1159/000524789 · Cited by 23
Self-citationAfereydoon, S., Haghiralsadat, F., Hamzian, N., Shams, A., Hemati, M., Naghib, S. M., Shabani, M., Zandieh‐Doulabi, B., & Tofighi, D. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.917368 · Cited by 26
“, 2021), and hormone therapy (Im et al., 2019) are the most common therapies used for the treatment of breast cancer.”
BackgroundChoong, G. M. Y., Liddell, S. S., Ferre, R. A. L., O'Sullivan, C. C., Ruddy, K. J., Haddad, T. C., Hobday, T. J., Peethambaram, P. P., Liu, M., Goetz, M. P., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06713-1 · Cited by 24
Mlinarić, Z., Turković, L., Begović, I., Nigović, B., & Sertić, M. (2022) · Molecules · doi:10.3390/molecules27217603 · Cited by 22
Ademuyiwa, F. O., Northfelt, D., O’Connor, T. L., Levine, E. G., Luo, J. R., Tao, Y., Hoog, J., Laury, M. L., Summa, T., Hammerschmidt, T., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-022-00504-z · Cited by 23
Prat, A., Solovieff, N., André, F., O’Shaughnessy, J., Cameron, D., Janni, W., Sonke, G. S., Yap, Y. S., Yardley, D. A., Partridge, A. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0561 · Cited by 25
Pascual, T., Fernández-Martínez, A., Agrawal, Y., Pfefferle, A. D., Chic, N., Brasó‐Maristany, F., González‐Farré, B., Paré, L., Villacampa, G. J., Saura, C., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00625-7 · Cited by 22
Grolmusz, V. K., Chen, J., Emond, R., Cosgrove, P. A., Pflieger, L. T., Nath, A., Moos, P. J., & Bild, A. H. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01337-1 · Cited by 24
Fuentes‐Antrás, J., de Luna, A., de Sá, A. L., Ocaña, A., García-Sáenz, J. Á., & Moreno, F. (2020) · The Breast · doi:10.1016/j.breast.2020.10.007 · Cited by 23
“In this regard, grade 3 elevation of alanine and aspartate aminotransferases occurred in up to 11% and 6% of patients receiving ribociclib or abemaciclib in RCTs [2,4,8].”
BackgroundInfluentialHusinka, L., Koerner, P., Miller, R. T., & Trombatt, W. D. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1857103 · Cited by 22
Rubovszky, G., Kocsis, J., Boér, K., Chilingirova, N. P., Dank, M., Kahán, Z., Kaidarova, D., Kövér, E., Vertáková-Krakovská, B., Máhr, K., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610383 · Cited by 23
“This combination showed an OS benefit in the MONALEESA-3 trial (91, 92) (ribociclib) for postmenopausal patients, and in the MONARCH-2 trial (93) in both pre-/perimenopause and postmenopause (abemaciclib) (I.”
BackgroundAchieving Improved Survival Outcomes in Advanced Breast Cancer
Rugo, H. S. (2019) · New England Journal of Medicine · doi:10.1056/nejme1906236 · Cited by 23
Schütz, F., Fasching, P. A., Welslau, M., Hartkopf, A. D., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1001-9925 · Cited by 21
Metadata
- Authors
- Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K.-H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S., & Tripathy, D.
- Affiliations
- Seoul National University (KR)
- Harvard University (US)
- From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) — all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard...
- Novartis (Switzerland) (CH)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 307-316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2948069739
- Cited by
- 1,001
- References
- 32
- Citations by year
- 2026: 68 · 2025: 119 · 2024: 121 · 2023: 152 · 2022: 159 · 2021: 165 · 2020: 174 · 2019: 42
- FWCI
- 100.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, endocrine therapy, hormone receptor-positive breast cancer, HER2-negative breast cancer, overall survival, aromatase inhibitors, goserelin, tamoxifen, progression-free survival, disease progression, second-line therapy, antineoplastic therapy, treatment-related adverse events, neutropenia
- MeSH terms
- Adult, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Follow-Up Studies, Humans, Middle Aged, Purines, Receptors, Estrogen, Receptors, Progesterone, Tamoxifen, Survival Analysis, Premenopause, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinases, Aromatase Inhibitors, Protein Kinase Inhibitors, Perimenopause, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.